Ruth María Erazo-Garnica

Ruth María Erazo-Garnica

Auto-generated profile, based on publicly available information

Ruth María Erazo-Garnica

Universidad de Antioquia, Programa de Posgrado, Reumatología Pediátrica, Medellin, Colombia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2019 in Colombia Medica
Verified
Journal Article
Open access
PDF file
CMCatalina Martinez-Jaramillo
Catalina Martinez-Jaramillo
SGSebastian Gutierrez-Hincapie
Sebastian Gutierrez-Hincapie
JAJulio César Orrego Arango
Julio César Orrego Arango
GVGloria María Vazuez-Duque
Gloria María Vazuez-Duque
RERuth María Erazo-Garnica
Ruth María Erazo-Garnica
CTClaudia Milena Trujillo-Vargas
Claudia Milena Trujillo-Vargas
Background: LPS-responsive beige -like anchor protein (LRBA) deficiency is a primary immunodeficiency disease caused by loss of LRBA protein expression, due to biallelic mutations in LRBA gene. LRBA deficiency patients exhibit a clinically heterogeneous syndrome. The main clinical complication of LRBA deficiency is immune dysregulation. Furthermore, hypogammaglobulinemia is found in more than half of patients with LRBA-deficiency. To date, no patients with this condition have been reported in Colombia Objective: To evaluate the expression of the LRBA protein in patients from Colombia with clinical phenotype associated to LRBA-deficiency. Methods: In the present study the LRBA-expression in patients from Colombia with clinical phenotype associated to LRBA-deficiency was evaluated. After then, the clinical, the immunological characteristics and the possible genetic variants in LRBA or other genes associated with the immune system in patients that exhibit decrease protein expression was evaluated. Results: In total, 112 patients with different clinical manifestations associated to the clinical LRBA phenotype were evaluated. The LRBA expression varies greatly between different healthy donors and patients. Despite the great variability in the LRBA expression, six patients with a decrease in LRBA protein expression were observed. However, no pathogenic or possible pathogenic biallelic variants in LRBA, or in genes related with the immune system were found. Conclusion: LRBA expression varies greatly between different healthy donors and patients. Reduction LRBA-expression in 6 patients without homozygous mutations in LRBA or in associated genes with the immune system was observed. These results suggest the other genetic, epigenetic or environmental mechanisms, that might be regulated the LRBA-expression.